Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group

Item

http://www.wikidata.org/entity/Q36097717

Q36097717

about

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma Targeted immunotherapy for pediatric solid tumors Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects Immunotherapy of Childhood Sarcomas Spinal osteosarcoma Cellular immunotherapy for pediatric solid tumors Children's Oncology Group's 2013 blueprint for research: bone tumors Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma Osteosarcoma Overview.Cardiovascular disease in adult survivors of childhood cancer.Epidemiology and therapies for metastatic sarcoma HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors.Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies.Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status.Molecular profiling of childhood cancer: Biomarkers and novel therapies Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma The Current and Future Therapies for Human Osteosarcoma.Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.Immunotherapy in pediatric malignancies: current status and future perspectives A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.Molecular mechanisms of chemoresistance in osteosarcoma (Review).Targeted therapy for soft tissue sarcomas in adolescents and young adults.The adolescent and young adult with cancer: state of the art -- bone tumors.Chemotherapy for osteosarcoma - where does it come from? What is it? Where is it going?Treatment-related cardiotoxicity in survivors of childhood cancer.Current therapeutic strategies and novel approaches in osteosarcoma.Advances in therapy for pediatric sarcomas.ErbB receptors as prognostic and therapeutic drug targets in bone and soft tissue sarcomas.The Potential of panHER Inhibition in Cancer.

P2860

Q26738598-9BD81532-D6A9-45F6-A6BE-1629A2D7BEE7 Q26747703-888E9E2A-601F-4B40-B0FC-7F21A37CE932 Q26750631-C53A947F-887E-4ECC-AF94-282DF90BA462 Q26753082-C13D2625-E9FD-4330-8CC3-F7B3E476D9A5 Q26795369-6369C2C3-0578-4FF5-83FE-BF97BCD0CD17 Q26996533-F26C2BE1-6DB6-4D41-8B78-5E0E7039E203 Q27014912-74162695-BB00-49D3-A705-E399A95DCC23 Q27027664-DDB460D3-2DB1-47A5-9050-7BFBD24C0D19 Q28082793-209DAA86-31DD-46D8-B2D8-11A70122B741 Q28386370-066BFFF2-A261-4639-9B35-7567645AB054 Q28552916-E0FEE384-686A-4C1C-80B9-9D11B6677004 Q33725511-18F18E8D-CEA0-4543-B7A9-F8F6C6548BF9 Q34042984-33B2F97F-A207-44EB-B462-F24CE0B0F734 Q34652142-B3C05486-D389-4BE9-8AC1-3ED162495EEE Q34887225-181179E6-5393-4435-9FCE-E3D4C16B5408 Q35562745-15B1B3C6-93B8-476D-B2B9-02598EAAD812 Q35598804-52776D49-148C-4936-ADC6-9FF92CD9C226 Q35826810-9455CE08-5EDF-40A7-B6B9-84A16AFB2017 Q35852826-3D9372C0-5896-4A72-9145-F8094C87E969 Q35894540-291CC33B-FDEA-474C-819B-8CA41DF3A155 Q36046928-C2DB72C8-A3EC-4E65-84C4-A18D80E041C6 Q36211310-44CC101A-6D46-46EC-8553-138107B23296 Q36250783-78CB6B5F-123E-4A28-A71F-ABBF928991AF Q36261159-0A49CA59-C435-40AD-9A6A-9829F8361BBF Q36316518-E8D9049F-DE11-45E8-B1A9-00360F7C8925 Q36514299-2A89393F-2271-4043-A4F1-57A5E934CA9F Q36649653-6538F47D-DE81-4990-9167-58EBD90747FD Q36691818-9B99A4D2-1580-414D-A1BA-AEC087628934 Q36888962-05BF2E5C-94E0-464B-BAFA-E870F17DFD5A Q37209968-AD06DBBA-023C-4F58-A025-408CBA5D38F1 Q37481150-01C893F4-CF77-4015-9CCE-25C5580ACFBB Q37719938-B88552B7-C0AB-4C73-B440-4565D3746F1A Q37742014-F4257A79-59B2-4B06-93D2-26B0587055F7 Q38108248-F4D6DABC-9203-4697-8894-9C43493E8487 Q38126943-A009AB3E-2DAC-4081-BDC0-5C6CF45C876A Q38156036-D3D45FCF-8C13-439E-996C-0036D548CAFC Q38161735-CF80E87F-56A2-4F75-80DD-F1FFCD3E3E83 Q38217354-B393396A-C03B-46E4-9029-3A905DAB2056 Q38263000-6D317E2C-90CB-437D-A4D5-67C92BCDBB8E Q38352587-F9E03C8A-B098-45E4-9D36-3D43A075C028

P2860

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group

Item

http://www.wikidata.org/entity/Q36097717

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Phase II trial of trastuzumab ...... the children's oncology group

@ast

Phase II trial of trastuzumab ...... the children's oncology group

@en

type

Item

label

Phase II trial of trastuzumab ...... the children's oncology group

@ast

Phase II trial of trastuzumab ...... the children's oncology group

@en

prefLabel

Phase II trial of trastuzumab ...... the children's oncology group

@ast

Phase II trial of trastuzumab ...... the children's oncology group

@en

P1476

Phase II trial of trastuzumab ...... the children's oncology group

@en

P2093

Allen Goorin

http://www.w3.org/2001/XMLSchema#string

David Ebb

http://www.w3.org/2001/XMLSchema#string

Donald A Barkauskas

http://www.w3.org/2001/XMLSchema#string

Gene P Siegal

http://www.w3.org/2001/XMLSchema#string

George Douglas Letson

http://www.w3.org/2001/XMLSchema#string

Holcombe Grier

http://www.w3.org/2001/XMLSchema#string

Karen Marcus

http://www.w3.org/2001/XMLSchema#string

Mark Bernstein

http://www.w3.org/2001/XMLSchema#string

Mark Krailo

http://www.w3.org/2001/XMLSchema#string

Meenakshi Devidas

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue.

Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

Anthracycline-associated cardiotoxicity in survivors of childhood cancer.

P304

2545-2551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.37.4546

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22665540

http://www.w3.org/2001/XMLSchema#string

P921

cytotoxicity

phase II clinical trial

overexpression

chemotherapy

P932

3397787

http://www.w3.org/2001/XMLSchema#string

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group

about

P2860

P2860

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932